The Eversense implantable CGM device has been making waves with its innovative functionality. Last week, Senseonics published Eversense CGM real-world data from the first U.S. users. The following information comes straight from the Business Wire press release for accuracy and clarity:
The real-world data demonstrated that the Eversense CGM System showed strong performance and safety over a 90-day sensor wear period, especially in the low glucose ranges. This data provides real-world evidence desired by patients, healthcare providers and payers on the clinical value and benefit of Eversense.
OVERALL PERFORMANCE
Wear-time – 83.6% (American Diabetes Association recommends 70% wear-time)
Time in Range – 62.3% between the ranges of 70 to 180 mg/dL
Time in Hypoglycemia – 1.2% at <54 mg/dL and only 4% at <70 mg/dL. Users spent only 1.7% of the nighttime in hypoglycemia (<54mg/dL)
Safety – No device or procedure related serious adverse events over the 90 days
Conclusion – The Eversense real-world data showed excellent glycemic results, sensor accuracy, and safety. This data demonstrates that the Eversense CGM System is a valuable tool for diabetes management.
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
